Eyenovia Pipeline
Product Development at Eyenovia
1. https://bit.ly/44BK4Zf | https://bit.ly/44IwR0K | 2. 2022 Delve Insights, Acute Ocular Pain Report | 3. Population of 40-55YO in the US = 60.8M A , 35% of this population has never needed corrected vision, Assumes product works in 33% of patients BA. Published by Erin Duffin, & 30, S. (2022, September 30). Population of the U.S. by sex and age 2021. Statista. Retrieved February 3, 2023, from https://bit.ly/45Rv3U6 B. What is 20/20 vision? University of Iowa Hospitals & Clinics. (n.d.). Retrieved February 3, 2023, from https://bit.ly/482g6jT | 4. https://bit.ly/3r2iOFu | 5. Theophanous C, Modjtahedi BS, Batech M, Marlin DS, Luong TQ, Fong DS. Myopia prevalence and risk factors in children. Clin Ophthalmol. 2018 Aug 29;12:1581-1587. doi: 10.2147/OPTH.S164641. PMID: 30214142; PMCID: PMC6120514. U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2021.| Banashefski B, Rhee MK, Lema GMC. High Myopia Prevalence across Racial Groups in the United States: A Systematic Scoping Review. J Clin Med. 2023 Apr 21;12(8):3045. doi: 10.3390/jcm12083045 | 6.https://bit.ly/3Rcqdwz. | 7. Frost & Sullivan, Prospectus, World Bank 370M Adjusted to fit patient criteria | 8. J&J Global Eye Health Survey 2020 | https://bit.ly/45EsCEM | 9. Frost & Sullivan, Prospectus, World Bank | 9A. Frost & Sullivan, Prospectus, World Bank 150M adjusted for the highest at risk patients, 1/3rd of children | 10. Korenfeld M, Walters T, Martel J, Nunez D, Wang L. A Phase 3 Study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension 0.05%) to Treat Inflammation and Pain after Cataract Surgery. ASCRS presentation. San Diego. May 5-8 2023.
MydCombi (Mydriasis)
MydCombi™ is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation). Eyenovia’s delivery technology is intended to make this part of the exam both faster and more comfortable for patients, reducing the number of doses for dilation and potentially minimizing dose-related side effects. This anesthetic free dilation is without overflow, so there is no need to wipe away excess drug that may fall out of the eye. MydCombi is delivered rapidly in a horizontal mist by the Optejet which by design has a shutter that opens and closes during dispensing to minimize risk of cross-contamination.
Apersure (Presbyopia)
Apersure™ is our specialized pilocarpine formula for treating presbyopia. Administered via Optejet® dispenser, it may offer advantages over traditional administration. The Optejet® allows easy self-dosing for about 3-4 hours of enhanced near vision. The Optejet administers 1/5 the volume of solution compared to a traditional eyedropper, eliminating the excessive overdosing and reducing systemic exposure and toxicity. Pilocarpine constricts the eye’s pupil, creating a “pinhole” effect that enhances depth of field. This method, previously used in contact lenses and surgery, is now offered in a less invasive way through Apersure.
MicroPine (Myopia)
MicroPine™ is our proprietary microdose formulation of low dose atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children. Moderate-to-severe myopia is associated with a lengthening of the eye. This can lead to significant stretching of tissues in the back-of-the eye causing permanent visual problems associated with retinal detachment, choroidal & retinal atrophy, and choroidal neovascularization1,2,3,4,5,6. In the US alone, there are approximately 25 million children with myopia, with up to 3 million considered to be at risk for high myopia and many times more that number in Asia5,7. Pathologic myopia is an important cause of vision loss worldwide, affecting up to 3% of the population.
1. Vongphanit, J., Mitchell, P., & Wang, J. J. (2002). Prevalence and progression of myopic retinopathy in an older population. Ophthalmology, 109(4), 704-711.
2. Ogawa, A., & Tanaka, M. (1988). The relationship between refractive errors and retinal detachment–analysis of 1,166 retinal detachment cases. Japanese journal of ophthalmology, 32(3), 310-315.
3. Lim, R., Mitchell, P., & Cumming, R. G. (1999). Refractive associations with cataract: the blue mountains eye study. Investigative ophthalmology & visual science, 40(12), 3021-3026.
4. Mitchell, P., Houriha4. n, F., Sandbach, J., & Wang, J. J. (1999). The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology, 106(10), 2010-2015.
5. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641.
6. Chia, Audrey, et al. “Five-Year Clinical Trial on Atropine for the Treatment of Myopia” Ophthalmology, vol. 123, no. 2, 2016, pp. 391–399., doi:10.1016/j.ophtha.2015.07.004.
7. U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2019.